PCL피씨엘

PCL is in court-supervised corporate rehabilitation and has a delisting filing, with heavy losses and debt.

PCL, a Korean in-vitro diagnostics maker, reported sharply falling revenue and large operating and net losses through the 2024 year-end and the trailing period to Q3 2025. In May 2026 it filed to start corporate rehabilitation proceedings, and an August 2026 filing is titled Delisting. Its trailing cash of ₩1.6B sits against borrowings of ₩8.4B.

What stands out

• Trailing revenue to Q3 2025 was about ₩5.0B, against a trailing operating loss of about ₩21.3B and a net loss of about ₩47.1B.
• Revenue has fallen every year shown, from about ₩46.1B in 2021 to ₩1.2B in 2024.
• Liabilities are about 529% of equity and trailing free cash flow was about -₩8.4B.
• The filings list shows a May 2026 corporate rehabilitation application and market notices on administrative issue designation grounds.
• Share price was ₩6,040 on 2026-10-20, with market value about ₩16.8B; the price data shows 0% returns over 1 month, 3 months and 1 year, and no 52-week range.

What to watch

• The August 2026 delisting filing and any court decision on the rehabilitation proceedings.
• Whether the company files newer financial statements; the latest figures in the data are for Q3 2025.
• The data does not include news headlines, analyst views or a fair value estimate, so these are not covered.